T3D Therapeutics Announces Presentation of Phase 2a Preliminary...

An investigational new drug, T3D-959, elicited rapid improvement in ADAS-cog11 cognitive tests in 53% of subjects with mild to moderate Alzheimer’s disease in an exploratory, open label Phase 2a...(PRWeb August 03, 2016)Read the full story at http://www.prweb.com/releases/2016/08/prweb13590398.htm
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Source Type: news